Cohance Lifesciences Limited has merged with and into Suven Pharmaceuticals Limited in a ~$3 billion (combined) merger. Following the merger, Suven Pharmaceuticals Limited has now been renamed as Cohance Lifesciences Limited.
JSA Advocates & Solicitors advised Advent International and Suven Pharma on this merger.
The transaction team was led by Iqbal Khan (Partner & National Corporate Lead) and Ambarish (Partner) with support from Krishaal Morjaria (Principal Associate), Tarini Sardesai (Senior Associate) and Associates Ayushi Choudhary and Raviraj Zinzuvadia.
Suven Pharma, backed by Advent International, is a publicly listed contract development and manufacturing organization (CDMO).
The merger aims to establish a diversified Contract Development and Manufacturing Organization platform, which will enhance their service offerings in the pharmaceutical sector.
The merger, effective May 1, 2025, received all regulatory approvals including from the NCLT and Department of Pharmaceuticals. Under the approved scheme, Cohance shareholders received 11 shares of Suven for every 295 shares held, resulting in Advent International holding a 66.7% stake in the combined entity.
The merger aims to create a leading integrated contract development and manufacturing organization (CDMO) focused on high-growth verticals like antibody-drug conjugates, oligonucleotides, and small molecules. The company is targeting ₹8,500 crore in annual revenue over the next five years through a mix of organic growth and strategic acquisitions.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.